Physician profile
Gabriel P Schwartz
NPI 1598148173
$165,743.89
in general payments reported to CMS, 2019-2025
8 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19K · 2022: $33K · 2023: $35K · 2024: $58K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Travel and Lodging: $28K · Consulting Fee: $5,315 · Food and Beverage: $4,872 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,342.50 |
| Travel and Lodging | $27,576.02 |
| Consulting Fee | $5,315.00 |
| Food and Beverage | $4,872.20 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $647.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $62,169.01 | 2021-2025 | Pemazyre, Pemazyre |
| Astrazeneca Pharmaceuticals Lp | $58,006.34 | 2022-2025 | Imfinzi, Calquence |
| Eisai INC. | $23,049.06 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17,211.65 | 2024-2025 | Fruzaqla |
| Exelixis INC. | $4,925.53 | 2021-2022 | |
| Amgen INC. | $164.00 | 2021 | |
| Abbvie INC. | $122.98 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $95.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.